Brought to you by 
Sanofi receives options on bispecific antibodies from Adimab
01 Feb 2023
Executive Summary
Adimab LLC optioned Sanofi exclusive rights to develop and sell bispecific and fully human therapeutic antibodies against multiple targets. During a certain period, Sanofi will be able to research the antibodies prior to option exercise.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi receives options on bispecific antibodies from Adimab
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice